Drug
Nkt2152
Nkt2152: highest development phase Phase 2, developed by NiKang Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- NiKang Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| NKT2152 NCT05935748 | Phase 2 | ccRCC |
Latest
No recent events.
Follow Nkt2152 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.